全文获取类型
收费全文 | 3575篇 |
免费 | 205篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 30篇 |
儿科学 | 62篇 |
妇产科学 | 67篇 |
基础医学 | 500篇 |
口腔科学 | 121篇 |
临床医学 | 221篇 |
内科学 | 941篇 |
皮肤病学 | 109篇 |
神经病学 | 319篇 |
特种医学 | 199篇 |
外科学 | 480篇 |
综合类 | 25篇 |
预防医学 | 315篇 |
眼科学 | 83篇 |
药学 | 147篇 |
中国医学 | 11篇 |
肿瘤学 | 168篇 |
出版年
2024年 | 2篇 |
2023年 | 31篇 |
2022年 | 69篇 |
2021年 | 134篇 |
2020年 | 74篇 |
2019年 | 103篇 |
2018年 | 117篇 |
2017年 | 80篇 |
2016年 | 95篇 |
2015年 | 124篇 |
2014年 | 166篇 |
2013年 | 180篇 |
2012年 | 284篇 |
2011年 | 274篇 |
2010年 | 166篇 |
2009年 | 134篇 |
2008年 | 242篇 |
2007年 | 267篇 |
2006年 | 265篇 |
2005年 | 206篇 |
2004年 | 214篇 |
2003年 | 186篇 |
2002年 | 157篇 |
2001年 | 32篇 |
2000年 | 27篇 |
1999年 | 21篇 |
1998年 | 33篇 |
1997年 | 14篇 |
1996年 | 16篇 |
1995年 | 10篇 |
1994年 | 8篇 |
1993年 | 4篇 |
1992年 | 6篇 |
1991年 | 6篇 |
1990年 | 4篇 |
1989年 | 2篇 |
1988年 | 3篇 |
1987年 | 3篇 |
1986年 | 3篇 |
1985年 | 2篇 |
1984年 | 5篇 |
1983年 | 2篇 |
1982年 | 8篇 |
1981年 | 5篇 |
1980年 | 2篇 |
1976年 | 3篇 |
1963年 | 2篇 |
1962年 | 1篇 |
1956年 | 1篇 |
1945年 | 1篇 |
排序方式: 共有3798条查询结果,搜索用时 15 毫秒
1.
Deitelzweig Steve Luo Xuemei Nguyen Jennifer L. Malhotra Deepa Emir Birol Russ Cristina Li Xiaoyan Lee Theodore C. Ferri Mauricio Wiederkehr Danny Reimbaeva Maya Barnes Geoffrey D. Piazza Gregory 《Journal of thrombosis and thrombolysis》2022,54(4):696-696
Journal of Thrombosis and Thrombolysis - 相似文献
2.
3.
4.
5.
6.
7.
8.
George Z Rassidakis Georgios V Georgakis Mauricio Oyarzo Anas Younes L Jeffrey Medeiros 《Modern pathology》2004,17(8):946-953
c-Kit receptor (CD117) is expressed by erythroid, megakaryocytic, and myeloid precursors and mature mast cells and has been reported to be expressed in CD30+ lymphomas such as Hodgkin's disease and anaplastic large-cell lymphoma. Imatinib mesylate, a well-established inhibitor of bcr-abl tyrosine kinase, and currently used for the treatment of patients with chronic myeloid leukemia, also inhibits c-kit receptor kinase activity. In view of the possible use of imatinib as experimental therapy for patients with c-kit-positive tumors, we assessed c-kit expression in CD30+ cell lines and lymphomas. The cell lines were assessed using multiple methods (RT-PCR, flow cytometry, and Western blot). c-Kit expression was also immunohistochemically assessed in 168 CD30+ lymphomas including 87 classical Hodgkin's disease, 63 anaplastic large-cell lymphoma, and 15 cutaneous anaplastic large-cell lymphoma. We also studied 18 cases of lymphomatoid papulosis, a CD30+ lesion closely related to cutaneous anaplastic large-cell lymphoma. Neither c-kit mRNA nor protein was detected in any of the cell lines assessed. Furthermore, treatment with imatinib did not inhibit proliferation of cell lines in vitro. Using immunohistochemistry, only one of 183 (0.5%) lesions was positive for c-kit, the positive case being an ALK-negative anaplastic large-cell lymphoma. Our data demonstrate that expression of c-kit receptor is exceedingly rare among CD30+ lymphomas and lymphomatoid papulosis, suggesting that c-kit receptor is unlikely to be an appropriate target for therapeutic options such as imatinib in patients with these tumors. 相似文献
9.
10.
Vitale C Cornoldi A Gebara O Silvestri A Wajngarten M Cerquetani E Fini M Ramires JA Rosano GM 《Menopause (New York, N.Y.)》2005,12(5):552-558
OBJECTIVE: The lack of a beneficial long-term cardiovascular effect of hormone therapy and the early incidence of cardiovascular adverse events observed in recent randomized studies have been related to a heightened inflammatory effect of hormone therapy. DESIGN: We evaluated the effect of different postmenopause therapies on inflammatory markers and endothelial function in 205 postmenopausal women before and after therapy. RESULTS: all postmenopausal women, estrogens alone increased plasma levels of C-reactive protein (CRP) but decreased all other markers of inflammation including interleukin-6 (IL-6) (CRP: +75% +/- 11%, intracellular adhesion molecule: -21% +/- 4%, vascular cell adhesion molecule: -15% +/- 6%, E-selectin: -18% +/- 4%, s-thrombomodulin -10.5% +/- 3.7%, IL-6 -14% +/- 6%; percent changes, P < 0.01 compared with baseline). Raloxifene and tibolone did not significantly affect the overall inflammatory milieu. In a minority of patients, estrogen-progestogen associations and tibolone increased IL-6 levels and induced unfavorable changes on inflammation markers (CRP: +93% +/- 8%, intracellular adhesion molecule: -3% +/- 2%, vascular cell adhesion molecule: -5% +/- 2%, E-selectin: +6% +/- 2%, s-thrombomodulin: +5% +/- 2%, IL-6: +12% +/- 4%; percent changes compared with baseline). Patients with increased IL-6 levels were older and had a longer time since menopause. In all patients except those with increased IL-6 levels, hormone therapy improved endothelial function, whereas tibolone and raloxifene did not significantly change endothelial function compared with baseline. A worsening of endothelial function was detected in patients with increased IL-6 levels during therapy. CONCLUSIONS: Postmenopausal hormone therapy is associated with decreased vascular inflammation; however, in patients with a longer time since menopause, postmenopause hormone therapy may increase inflammation and worsen endothelial function. These unfavorable vascular effects may be detected by an elevation in IL-6 levels and by a lack of improvement in endothelial function. 相似文献